Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission

PURPOSE: To evaluate whether autologous cytokine-induced killer (CIK) cell immunotherapy improves the prognosis of patients with high-risk diffuse large B cell lymphoma (DLBCL) after the first complete remission (CR). PATIENTS AND METHODS: Peripheral blood mononuclear cells (PBMCs) were extracted fr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Zhou, Min, Wang, Jing, Li, Cui-Ping, Xu, Jing-Yan, Chen, Bing
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7319512/
https://ncbi.nlm.nih.gov/pubmed/32606798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S254291
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky